Lee Jeong Won, Paeng Jin Chul, Kang Keon Wook, Kwon Hyun Woo, Suh Kyung-Suk, Chung June-Key, Lee Myung Chul, Lee Dong Soo
Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea.
J Nucl Med. 2009 May;50(5):682-7. doi: 10.2967/jnumed.108.060574. Epub 2009 Apr 16.
Although several prognostic factors are used to predict recurrence and to select adequate candidates for liver transplantation for hepatocellular carcinoma (HCC), these prognostic factors have some clinical limitations. The purpose of this study was to evaluate (18)F-FDG PET as a prognostic factor and to optimize its ability to predict tumor recurrence in liver transplantation for HCC.
The study included a total of 59 HCC patients (45 men and 15 women; mean age +/- SD, 56 +/- 8 y) who underwent (18)F-FDG PET and subsequent orthotopic liver transplantation. All patients were followed up for more than 1 y (mean, 29 +/- 17 mo), and recurrence of tumor was monitored. Three PET parameters-maximal standardized uptake value (SUV(max)), ratio of tumor SUV(max) to normal-liver SUV(max) (T(SUVmax)/L(SUVmax)), and ratio of tumor SUV(max) to normal-liver mean SUV (T(SUVmax)/L(SUVmean))-were tested as prognostic factors and compared with conventional prognostic factors.
Among the 3 parameters tested, T(SUVmax)/L(SUVmax) was the most significant in the prediction of tumor recurrence, with a cutoff value of 1.15. In a multivariate analysis of various prognostic factors including T(SUVmax)/L(SUVmax), serum alpha-fetoprotein, T stage, size of tumor, and vascular invasion of tumor, T(SUVmax)/L(SUVmax) was the most significant, and only vascular invasion of tumor had additional significance. According to T(SUVmax)/L(SUVmax), the 1-y recurrence-free survival rate above the cutoff was markedly different from the rate below the cutoff (97% vs. 57%, P < 0.001).
In this study, (18)F-FDG PET was an independent and significant predictor of tumor recurrence. In liver transplantation for HCC, (18)F-FDG PET can provide effective information on the prognosis for tumor recurrence and the selection of adequate candidates for liver transplantation.
尽管有多种预后因素可用于预测肝细胞癌(HCC)的复发并选择合适的肝移植候选者,但这些预后因素存在一些临床局限性。本研究的目的是评估(18)F-FDG PET作为一种预后因素,并优化其预测HCC肝移植中肿瘤复发的能力。
本研究共纳入59例HCC患者(45例男性和15例女性;平均年龄±标准差,56±8岁),这些患者接受了(18)F-FDG PET检查及随后的原位肝移植。所有患者均随访超过1年(平均,29±17个月),并监测肿瘤复发情况。测试了三个PET参数——最大标准化摄取值(SUV(max))、肿瘤SUV(max)与正常肝脏SUV(max)的比值(T(SUVmax)/L(SUVmax))以及肿瘤SUV(max)与正常肝脏平均SUV的比值(T(SUVmax)/L(SUVmean))——作为预后因素,并与传统预后因素进行比较。
在测试的三个参数中,T(SUVmax)/L(SUVmax)在预测肿瘤复发方面最为显著,临界值为1.15。在对包括T(SUVmax)/L(SUVmax)、血清甲胎蛋白、T分期、肿瘤大小和肿瘤血管侵犯等多种预后因素的多变量分析中,T(SUVmax)/L(SUVmax)最为显著,且只有肿瘤血管侵犯具有额外的显著性。根据T(SUVmax)/L(SUVmax),临界值以上的1年无复发生存率与临界值以下的生存率明显不同(97%对57%,P<0.001)。
在本研究中,(18)F-FDG PET是肿瘤复发的独立且显著的预测指标。在HCC肝移植中,(18)F-FDG PET可为肿瘤复发的预后及合适的肝移植候选者的选择提供有效信息。